Resilience and adaptation are often seen as admirable traits in humans, but when demonstrated by pathogens, they can lead to severe consequences. Bacteria, viruses, and fungi that evolve to resist treatments contribute to antimicrobial resistance (AMR), making it an escalating challenge for healthcare professionals worldwide. Studies indicate that in the next 25 years, AMR-related deaths may surpass those caused by cancer and other major diseases. Dr. Y.K. Hamied, chairman of Cipla, describes this issue as ‘Anti Microbial Mis Use’ (AMMU), highlighting how self-medication, overuse, and misuse of antibiotics have fueled this crisis. With no new antibiotics emerging to replace older ones, the problem continues to grow.
The evolving nature of bacteria and viruses raises concerns about the future of medicine, prompting researchers to explore new approaches to tackling infectious diseases. While existing medications can be stretched for a few more decades, investments in alternative treatments and novel technologies are crucial. Some experts envision advancements such as nanobots circulating in the bloodstream, a concept already being explored at MIT. The ineffectiveness of medications is not limited to complex diseases; even treatments for common ailments like fever and colds can become less effective due to misuse.
Drug resistance is only one part of the challenge. Climate change further complicates healthcare by enabling the spread of disease-carrying vectors, such as mosquitoes, into previously unaffected regions. Rising temperatures have expanded the reach of malaria and other infections. However, advancements in technology are transforming medicine in profound ways. Artificial intelligence aids in risk profiling, while automated insulin delivery through pager-sized devices mimics an artificial pancreas. Genomics-driven diagnostics are enabling precision treatments for diseases such as cancer. Future possibilities include nanobots repairing tissues at the cellular level, gene-editing breakthroughs, and robotic-assisted treatments targeting DNA.
Medical innovation continues to push boundaries, but access to new therapies remains a significant concern. Advanced treatments can be prohibitively expensive, placing them out of reach for many. For example, drugs like Ozempic and Wegovy, used for diabetes and weight management, cost approximately $1,000 per month in the United States. While pricing strategies may be adjusted for the Indian market, affordability remains a challenge. Yet, when patent restrictions are absent, Indian pharmaceutical companies have demonstrated a strong ability to produce cost-effective generic alternatives, making essential medications widely available.
Cost remains a critical factor in the future of medicine, but genomics is making significant strides toward affordability. Vijay Chandru, a pioneer in leveraging genomics for medical diagnostics, highlights the exponential drop in sequencing costs over the past two decades. What once cost millions of dollars is now within reach for a fraction of the price, paving the way for democratized healthcare. High-quality genome sequencing, once an expensive procedure, is now available at a much lower cost, offering new possibilities for early detection and preventive care.
Despite setbacks in the gene-editing space, experts remain optimistic about its potential. Every technological breakthrough undergoes phases of hype and disillusionment before reaching widespread adoption. In the case of CRISPR technology, ongoing refinements and targeted applications will determine its success. For companies in the gene-editing sector, developing diagnostic products alongside therapeutics ensures financial sustainability and attracts investment.
The possibility of gene-edited humans is no longer confined to science fiction. CAR-T cell therapy, an innovative immunotherapy for blood cancers, has rapidly progressed, with treatments now available in India at a fraction of the cost seen in Western markets. The infrastructure required to advance from CAR-T therapy to full-fledged gene therapy is within reach, with several research teams actively working in this area. Discussions on the ethical and social implications of gene editing continue, with international forums set to address these concerns in the coming years.
Oncology, a constantly evolving field, has undergone significant transformation over the past decade. Earlier, treatments were based on generalized approaches derived from randomized trials. Now, with a deeper understanding of cancer at the molecular level, therapies have become more precise and personalized. Antibody-drug conjugates and targeted treatments are tailored to an individual’s specific genetic profile. The traditional classification of cancer by organ type is becoming less relevant, as treatment decisions now hinge on unique genetic markers. Furthermore, survival rates are improving, with patients diagnosed at advanced stages responding well to cutting-edge treatments and living longer than previously expected.
